Schweizerische Gesellschaft für SENOLOGIE

Société Suisse de Sénologie
Società Svizzera di Senologia

PROGRAM

ANNUAL CONGRESS OF THE SWISS SOCIETY OF SENOLOGY



MIBB certification course for breast vacuum biopsies

Hands-on Innovative Techniques and Vacuum Biopsies

Wednesday, **September 20, 2023**

Brust-Zentrum Zürich
Seefeldstrasse 214, 8008 Zürich

BRUST-ZENTRUM ZÜRICH

MIBB Minimally Invasive Breast Biopsies
Working Group of the Swiss Society of Senology

MIBB Symposium

Thursday, **September 21, 2023**

Congress of the Swiss Society of Senology

Thursday, **September 21, 2023**
Friday, **September 22, 2023**

Technopark Zürich
Technoparkstrasse 1, 8005 Zürich

Congress Secretariat sabine.gisler@meeting-com.ch

Invitation

Dear Colleagues,

We would like to welcome you to the next MIBB hands-on course and MIBB symposium, joint with the Swiss Society of Senology Congress. By attending the theoretical and practical course on Wednesday afternoon, you will meet an essential prerequisite to become a certificated MIBB-operator for vacuum-assisted breast biopsies (VAB). We have onboard excellent hands-on teachers and instructors for ultrasound-, mammography-, and MRI-guided VAB. The number of places is limited to guarantee an excellent training setting.

The MIBB symposium on Thursday morning focuses on current and future challenges in breast diagnostics, presented by national and international experts. We will discuss about quality improvement of VAB, B3-lesions, breast imaging in transgender patients, breast-CT and contrast-enhanced mammography. The bridging lecture on breast cancer screening in Switzerland will lead to the Swiss Society of Senology Congress.

We are looking forward to meeting you in Zurich.

Kind regards,

Dr. Constanze Elfgen
MIBB President

Dr. Sabine Zehbe
MIBB Co-President

Invitation

Dear Colleagues,

This year`s annual meeting of the Swiss Society for Senology will take place from 21st to 22nd September at the Technopark in Zürich. The program highlights a wide variety of aspects of senology and we were able to win a number of internationally renowned speakers for this meeting in addition to wellknown experts from Switzerland.

Already in the morning of 21st of September the MIBB-Symposium will take place with a varied program all about the radiological and minimally invasive diagnosis of breast diseases. The annual conference starts at noon with a session on new possibilities in mammography screening, an overview of current approaches in the diagnosis and therapy of genetically caused breast cancer.

On the second day we will discuss new aspects in the neoadjuvant setting, the interdisciplinary treatment of metastatic breast cancer, complication- and error-management in senology, and the various treatment options for breast cancer associated chronic lymph edema.

We wish you an exciting MIIB-Symposium and Senology Congress, a lively interdisciplinary exchange and enjoy two wonderful days in Zurich together with the entire senology community. We look forward to welcoming you to Zurich in autumn.

PD Dr. med. Christoph Tausch
President Swiss Society for Senology

Dr. med. Constanze Elfgen
President MIBB-Group

Daiichi-Sankyo | AstraZeneca

ANNUAL CONGRESS OF THE SWISS SOCIETY OF SENOLOGY – 2023



From HER2-positive to HER2-low: Clinical Decision Making in the Rapidly Evolving Field of Advanced Breast Cancer

SPONSORED SYMPOSIUM

21st September 2023 I 12:00 – 13:00

Chair
PD Dr. Khalil Zaman
Lausanne University Hospital
CHUV

Dr. Giampaolo Bianchini
Ospedale San Raffaele, Italia

Prof. Jens Huober
Breast Center
Kantonsspital St. Gallen

Prof. Cornelia Leo
Breast Center
Kantonsspital Baden

AD0230391_CH-05/23

REGISTRATION

MIBB SYMPOSIUM & ANNUAL SSS CONGRESS – 2023

Access the Program:
https://www.meeting-com.ch/congres-evenements/details-evenement/events/mibb-symposium-annual-sss-congress-2023/

Organisation

MIBB President	Constanze Elfgen, Zurich
MIBB Co-President	Sabine Zehbe, St. Gallen
SSS Congress President	Christoph Tausch, Zürich
Organising Committee	Liliana Castrezana, Baden Constanze Elfgen, Zürich Jens Huober, St. Gallen Elisabeth A. Kappos, Basel Michael Knauer, St. Gallen Cornelia Leo, Baden Gunilla Müller, Zürich Claudia Rauh, Bern Christoph Tausch, Zürich

SSS Board

President	Christoph Tausch, Zürich
Past president	Martin Haug, Basel
1st Vice-president	Cornelia Leo, Baden
2nd Vice-president	Zsuzsanna Varga, Zürich
1st Assessor	Walter Weber, Basel
2nd Assessor	Salome Riniker, St. Gallen
General Secretary	Michael Knauer, St. Gallen
Treasurer	Felix Haberthür, Binningen

General information

Hands-on Course
Wednesday, September 20, 2023
Brust-Zentrum Zürich
Seefeldstrasse 214
8008 Zürich
www.brust-zentrum.ch

Congress venue MIBB & SSS congress
Thursday 21 & Friday 22 September 2023
Technopark Zürich
Technoparkstrasse 1
8005 Zürich

Registration & Congress Secretariat
Meeting.com Congress Organisation
Rue des Pâquis 1
CH-1033 Cheseaux-sur-Lausanne
T 021 312 92 61
F 021 312 92 63
sabine.gisler@meeting-com.ch
Online registration on www.meeting-com.ch

Certificate of attendance
The certificate of attendance together with the link for the authorized lectures will be sent by mail after the congress

Language / Lectures
Each speaker can present in his or her own language, but the slides are in **English**

Congress certification by DGS/DAS

General information

Credits
Credit points will be given by the following societies:

MIBB Certification course (Hands-on)

Swiss Society of Radiology (SSR)	6 credits
Swiss Society for Gynaecology and Obstetrics (SGGG)	6 credits
Swiss Society of Surgery (SSC)	4 credits

MIBB Symposium & SSS congress

Swiss Society of Radiology (SSR)	6 credits
Swiss Society for Gynaecology and Obstetrics (SGGG)	13 credits
Swiss Society of Surgery (SSC)	20 credits
Swiss Society for plastic, reconstructive and aesthetic surgery (SGPRAC)	12 credits
Swiss Society of Pathology (SGPath) as expanded continuing education	11 credits
Swiss Society of Medical Oncology (SSMO)	13 credits
Swiss Society for Radiation Oncology (SSRO)	13 credits

Posters
The abstracts accepted as posters will be presented during the congress
Dimensions of posters: height 120 cm x width 90 cm (portrait)
Deadline August 15, 2023

SGS/SSS Poster Award
Poster presentations will take place on Thursday, September 21, 2023 from 14.30-15.30.
The Awards Ceremony will take place during the Networking Dinner on Thursday evening.

Industrial Exhibition
An industrial exhibition will take place at the Congress venue on Thursday 21 and Friday 22 September 2023

General information

Registration fees	Early until 30.06.23	Regular until 31.08.23	Late & Onsite as from 01.09.23
MIBB & CONGRESS SSS **September 21-22, 2023** Technopark Zürich			
SSS MEMBER	❒ CHF 360.00	❒ CHF 420.00	❒ CHF 490.00
*Young SSSenologists Members	❒ CHF 260.00	❒ CHF 320.00	❒ CHF 360.00
SSS NON-MEMBER	❒ CHF 450.00	❒ CHF 510.00	❒ CHF 590.00
Assistant Doctor	❒ CHF 260.00	❒ CHF 320.00	❒ CHF 380.00
Student/BCN	❒ CHF 220.00	❒ CHF 270.00	❒ CHF 320.00

*** Prerequisite is membership of the SSS with indication of date of birth (under 40 years old)**

1 day participation: 50 % of the above-mentioned fees/registration **onsite** only

NETWORKING DINNER – September 21, 2023, 19.30
Zunfthaus zur Saffran
Limmatquai 54
CH-8001 Zürich
www.zunfthauszursaffran.ch ❒ CHF 120.00

MIBB CERTIFICATION COURSE Limited places
Wednesday September 20, 2023 (12.00-18.20)
Brust-Zentrum Zürich
Participant ❒ CHF 300.00 ❒ CHF 370.00

Registration fees include
Attendance & certificate of participation for the chosen events; coffee breaks & lunch according to the program. In case of cancellation 30 days prior to the event, course costs will be refunded, minus an administration fee of CHF 60.00. Thereafter no refund is possible. Please remember to pay the “early bird fee” by the 30th of June, otherwise the invoice will automatically update to the price valid as of 1st July onwards.

MIBB Hands-on

BRUST-ZENRUM ZÜRICH

Wednesday, September 20, 2023

Language
English

Organizing committee
Constanze Elfgen
Sabine Zehbe

Registration site / catering
Brust-Zentrum Zürich — 2ND FLOOR

Lectures
Brust-Zentrum Zürich — GROUND FLOOR

Hands-On please follow the signposts
US-Vab: 2nd floor
MG-VAB: 1st floor on the right
MR-VAB: Basement

11.00-12.00 **Registration & welcome coffee**

12.00-12.10 **Welcoming & introduction**
Constanze Elfgen/Christoph Tausch, Zürich; Sabine Zehbe, St. Gallen

MIBB certification course for breast vacuum biopsies

12.10-12.30 MIBB History, Activities and Adjumed Database
Sabine Zehbe, St. Gallen

12.30-12.50 Data reporting and its benefits for my patient, my institut and for myself
Martina Maranta, Chur

12.50-13.15 Ultrasound guided VAB: Tips and Tricks
Constanze Elfgen, Zürich

13.15-13.40 Stereotactically/Tomo- guided VAB: Tips and Tricks
Noemi Schmidt, Basel

13.40-14.05 MR- guided VAB: Tips and Tricks
Sabine Zehbe, St. Gallen

14.05-14.30 Coffee break

MIBB Hands-on

BRUST-ZENRUM ZÜRICH

Wednesday, September 20, 2023

14.30-14.45 **Allocation to the workstations**
Christoph Tausch

14.45-15.45 **Course A** Hands-On US-VAB
Constanze Elfgen/Uwe Güth, Zürich; Martina Maranta, Chur; Simone Schrading, Luzern

Course B Hands-On MG-VAB
Martin Müller, Zürich

Course C Hands-On MR-VAB
Sabine Zehbe, St. Gallen

15.45-16.45 **Course C** Hands-On US-VAB
Constanze Elfgen/Uwe Güth, Zürich; Martina Maranta, Chur; Simone Schrading, Luzern

Course A Hands-On MG-VAB
Carmen Dannecker, Zürich

Course B Hands-On MR-VAB
Sabine Zehbe, St. Gallen

16.45-17.45 **Course B** Hands-On US-VAB
Constanze Elfgen/Uwe Güth, Zürich; Martina Maranta, Chur; Simone Schrading, Luzern

Course C Hands-On MG-VAB
Martin Müller, Zürich

Course A Hands-On MR-VAB
Noemi Schmidt, Basel

17.45-18.00 **All 3 groups back to the lecture room**

18.00-18.20 **Final Discussion and Good-bye**
Hand out of certificates

MIBB Symposium

TECHNOPARK ZÜRICH

Thursday, September 21, 2023

08.00 **Registration**

09.00-09.05 **Welcome**
Constanze Elfgen, Zürich

09.00-11.30 MIBB Symposium **AUDITORIUM GROUND FLOOR**
Chairs: Martina Maranta, Chur; Susanne Bucher, Luzern

09.05-09.20 B3 lesions: results from the 3rd Consensus Conference 2022
Constanze Elfgen, Zürich

09.20-09.40 VAB: what lessons we have learned
Daniela Schwegler-Guggemos, Aarau

09.40-10.00 VAB: does needle size matter?
Zsuzsanna Varga, Zürich; Noemi Schmidt, Basel

10.00-10.30 Coffee break

10.30-10.50 Will there be a role for Breast-CT and contrast-enhanced mammography?
Andreas Boss, Wetzikon

10.50-11.15 Breast imaging in transgender patients
Andreas Gutzeit, Luzern

11.15-11.30 Challenges and chances on the horizon: from cantonal to nation-wide screening
Gunilla Müller, Zürich

11.30-13.00 Lunch

12.00-13.00 **SPONSORED SATELLITE SYMPOSIUM BY DAIICHI-SANKYO** **AUDITORIUM GROUND FLOOR**
Daiichi-Sankyo | AstraZeneca
From HER2-positive to HER2-low: Clinical Decision Making in the Rapidly Evolving Field of Advances Breast Cancer
Chair: Khalil Zaman, Lausanne
Speakers: Giampaolo Bianchini, Milan (IT); Jens Huober, St. Gallen / Cornelia Leo, Baden

SSS Congress

TECHNOPARK ZÜRICH

Thursday, September 21, 2023

13.15-13.20 **Welcome**
Christoph Tausch, Zürich

13.20-14.30 Block 1 **AUDITORIUM GROUND FLOOR**
New possibilities in modern screening
Chairs: Gunilla Müller, Zürich; Martin Sonnenschein, Bern

13.20-13.35 Why does breast cancer screening have a bad reputation in Switzerland?
Chris de Wolf, Onex

13.35-13.50 Is tomorrow's screening risk-based?
Mireille Broeders, Nijmegen (NL) *virtual presentation*

13.50-14.05 The current evidence of breast tomosynthesis in screening
Sophia Zackrisson, Malmö (SE) *virtual presentation*

14.05-14.20 Can AI replace the second reader in screening programs?
Ritse Mann, Amsterdam (NL) *virtual presentation*

14.20-14.30 Discussion

14.30-15.30 Coffee break and poster presentations

15.30-17.00 Block 2 **AUDITORIUM GROUND FLOOR**
Genetics
Chairs: Cornelia Leo, Baden; Salome Riniker, St. Gallen

15.30-16.00 Polygenic risk score: the new kid on the block
Marc Tischkowitz, Cambridge (UK)

16.00-16.20 Risk-reducing surgery beyond BRCA: current recommendations
Kathrin Schwedler, Luzern

16.20-16.40 Therapeutic options in BRCA-related breast cancer
Elena Kralidis, Zürich

16.40-17.00 BRCA mutations and fertility issues
Alexandra Kohl Schwartz, Luzern

17.00 General Assembly SSS/SGS

19.30 Networking Dinner & Awards Ceremony **ZUNFTHAUS ZUR SAFFRAN**

SSS Congress

TECHNOPARK ZÜRICH

Friday, September 22, 2023

07.30 **Registration**

08.30-10.15 Block 3 — AUDITORIUM GROUND FLOOR

New aspects of the neoadjuvant approach
Chairs: Peter Dubsky, Luzern; Khalil Zaman, Lausanne

08.30-08.55 Ovarian protection under neoadjuvant therapy
Matteo Lambertini, Genova (IT) *virtual presentation incl. discussion*

08.55-09.15 Neoadjuvant endocrine therapy:
A different strategy to individualize adjuvant decisions
Eva Maria Ciruelos Gil, Madrid (ES) *virtual presentation incl. discussion*

09.15-09.35 Is targeted axillary dissection after neoadjuvant therapy useful for every N-status?
Andreas Günthert, Luzern

09.35-09.55 Do we need surgery of the breast in case of radiological complete response?
Christoph Tausch, Zürich

09.55-10.15 Targeted axillary dissection versus sentinel node procedure to determine pathologic complete response in the axilla
Walter Weber, Basel

10.15-10.45 Coffee break

10.45-12.10 Block 4 — AUDITORIUM GROUND FLOOR

Metastatic breast cancer
Chairs: Jens Huober, St. Gallen; Pelagia Tsoutsou, Genève

10.45-11.05 Advanced breast cancer – principles of treatment
Nadia Harbeck, München (DE) *virtual presentation incl. discussion*

11.05-11.35 Interdisciplinary therapy of brain metastases:
radiotherapy/surgery/systemic therapy
Radiotherapy: Sébastien Tran, Genève
Surgery: Marian Neidert, St. Gallen
Oncology: Khalil Zaman, Lausanne
Discussion

11.35-11.47 Treatment options in Triple negative breast cancer – Marcus Vetter, Liestal

11.48-12.00 Precision medicine in MBC – ready to go? – Stefan Aebi, Luzern

12.00-12.10 Discussion

12.10-13.30 Lunch

SSS Congress

TECHNOPARK ZÜRICH

Friday, September 22, 2023

12.30-13.20 **SPONSORED WORKSHOP BY SIRIUS PINTUITION** — COBOL 2ND FLOOR

sirius medical

Navigation marker for mamma and axilla lesions
Clinical experience and hands-on workshop with breast phantoms
Cornelia Leo, Baden; Christoph Tausch, Zürich

12.30-13.15 **SPONSORED SATELLITE SYMPOSIUM BY GILEAD** — AUDITORIUM GROUND FLOOR

GILEAD

Integrative patient care in advanced Breast Cancer – Exploring new horizons
Chair: Isabell Witzel, Universitätsspital Zürich
Speakers: Daniela Paepke, Spital Zollikerberg;
Marcus Vetter, Kantonsspital Baselland

13.30-15.00 Block 5 — AUDITORIUM GROUND FLOOR

Complications and failures in senology
Chairs: Claudia Rauh, Bern; Constanze Elfgen, Zürich

13.30-13.45 Avoidance and management of side effect under systemic therapy-how to choose wisely
Alexandre Bodmer, Genève

13.45-14.00 Breast cancer survivorship – long-term medical issues and lifestyle recommendations
Maria Wertli, Baden

14.00-14.15 Dealing with challenges- a patient's view
Julia Curty, Biel

14.15-14.30 Surgical risks: how to avoid failure
Inga Bekes, St. Gallen

14.30-15.00 **Keynote Lecture**
Patient safety and reduction of healthcare harm
David Schwappach, Bern

15.00-15.30 Coffee break

SSS Congress

TECHNOPARK ZÜRICH

Friday, September 22, 2023

15.30-17.00 Block 6 — **AUDITORIUM GROUND FLOOR**

State of the art management of chronic lymphedema
Chairs: Elisabeth A. Kappos, Basel; Michael Knauer, St. Gallen

15.30-15.45	The senologist's perspective: de-escalation of axillary surgery Michael Knauer, St. Gallen
15.45-16.00	The physiotherapist's perspective: conservative treatment Yvette Stoel, Winterthur
16.00-16.15	The reconstructive surgeon's perspective: surgical algorithm Yves Harder, Lugano
16.15-16.30	Perspective of the rehabilitation specialist: maintenance therapy Martha Földi, Hinterzarten (DE)
16.30-16.45	The LYMPH Trial: better quality of life thanks to super microsurgery Elisabeth A. Kappos, Basel
16.45-17.00	Discussion

17.00 **Farewell**

Exhibition plan



1. INTELLIMED
2. SAMANTREE MEDICAL
3. INCEPTO MEDICAL
4. VERACYTE
5. MENGES
6. HOLOGIC
7. NOVARTIS
8. SEAGEN
9. MYRIAD
10. GILEAD
11. PFIZER
12. DIGITALXRAY
13. ROCHE PHARMA
14. NEODYNAMICS
15. B-RAYZ
16. SIRIUS
17. DAICHII
18. BD
19. EXACT SCIENCES

Speakers / Chairs

Prof. Stefan AEBI
Chefarzt Medizinische Onkologie
Luzerner Kantonsspital

PD Dr. Inga BEKES
Stv. Chefärztin / Brustchirurgie
Brustzentrum Kantonsspital St. Gallen

Dr. Giampaolo BIANCHINI
Head of breast oncology pathology,
IRCCS Ospedale San Raffaele, Milan (IT)

Dr. Alexandre BODMER
Médecin adjoint responsable,
Unité d'oncogynécologie, Hôpitaux
Universitaires Genève

Prof. Andreas BOSS
Chefarzt Radiologie, GZO Spital Wetzikon

Prof. Mireille BROEDERS
Personalized Cancer Screening,
Radbound University, Nijmegen (NL)

Dr. Susanne BUCHER
Co-Chefärztin und Leiterin Brustzentrum,
Luzerner Kantonsspital

Dr. Eva Maria CIRUELOS GIL
Médecin assistant, Service d'oncologie
médicale, Coordonnatrice de l'unité
de cancer du sein et gynécologique,
Hôpital 12 de Octubre, Madrid (ES)

Frau Julia CURTY
Breast Cancer Survivor & Member of
EUROPA DONNA Schweiz

Dr. Carmen DANNECKER
Consultant Radiologie, Brust-Zentrum
Zürich

Prof. Chris DE WOLF
Facharzt / Consultant Public Health cancer
screening

Prof. Peter Dubsky
Leiter Brustzentrum, Hirslanden Klinik
St. Anna, Luzern

Dr. Constanze ELFGEN
Leitung Brustchirurgie, Brust-Zentrum
Zürich

Dr. Martha FÖLDI
Fachärztin für Gynäkologie & Geburtshilfe,
Földiklinik Hinterzarten (DE)

Prof. Andreas GÜNTHERT
Gynäkologie und Geburtshilfe
gyn-zentrum, Luzern

Prof. Uwe GÜTH
Brustchirurg, Leitung Qualitätsmanagement,
Brust-Zentrum Zürich

Prof. Andreas GUTZEIT
Institut für Radiologie und Nuklearmedizin,
Klinik St. Anna, Luzern

Prof. Nadia HARBECK
Leitung, Brustzentrum und Onkologische
Tagesklinik der Frauenklinik, LMU Klinikum
München (DE)

Prof. Yves HARDER
Primario Chirurgia Plastica, Ricostruttiva
ed Estetica Ospedale Regionale di Lugano

Prof. Jens HUOBER
Chefarzt Brustzentrum Kantonsspital
St. Gallen

Speakers / Chairs

PD Dr. Elisabeth A. KAPPOS
Kaderärztin Plastische Chirurgie,
Universitätsspital Basel

Prof. Michael KNAUER
Brustchirurgie, Tumor- und Brustzentrum
Ostschweiz

PD Dr. Alexandra KOHL SCHWARTZ
Co-Chefärztin Reproduktionsmedizin,
Luzerner Kantonsspital

Dr. Elena KRALIDIS
Leitung Onkologie, Brust-Zentrum Zürich

Prof. Matteo LAMBERTINI
Associate Professor and consultant in
medical oncology, University of Genova –
IRCCS Ospedale Policlinico San Martino (IT)

Prof. Cornelia LEO
Leiterin Interdisziplinäres Brustzentrum,
Kantonsspital Baden

PhD Ritse MANN
Breast and interventional radiologist,
Netherlands Cancer Institute, Amsterdam
(NL)

Dr. Martina MARANTA
Leitende Ärztin Gynäkologie,
Kantonsspital Graubünden

Dr. Gunilla MÜLLER
Leitende Ärztin, Institut für Radiologie und
Nuklearmedizin, Stadtspital Triemli, Zürich

Dr. Martin MÜLLER
Leitung Radiologie, Brust-Zentrum Zürich

PD Dr. Marian NEIDERT
Stv. Chefarzt, Klinik für Neurochirurgie,
Kantonsspital St Gallen

Dr. Daniela PAEPKE
Fachärztin für Gynäkologie und
Geburtshilfe, Spital Zollikerberg

PD Dr. Claudia RAUH
Leitende Ärztin Brustzentrum, Inselspital
Bern

Dr. Salome RINIKER
Medizinische Onkologie Tumor-
und Brustzentrum Ostschweiz

Dr. Noemi SCHMIDT
Leiterin der Mammadiagnostik,
Universitätsspital Basel

PD Dr. Simone SCHRADING
Leitende Ärztin, Radiologie und
Nuklearmedizin, Luzerner Kantonsspital

Prof. David SCHWAPPACH
Institute of Social and Preventive Medicine
University of Berne

Dr. Kathrin SCHWEDLER
Leitende Ärztin, Frauenklinik, Luzerner
Kantonsspital

Dr. Daniela SCHWEGLER-GUGGEMOS
Leitende Ärztin Radiologie, Kantonsspital
Aarau

Dr. Martin SONNENSCHEIN
Facharzt für diagnostische Radiologie,
Brustzentrum Lindenhofgruppe, Klinik
Engeried, Bern

Yvette STOEL
Physiotherapeutin, klinische Spezialistin für
Lymphologie, Kantonsspital Winterthur

Speakers / Chairs

PD Dr. Christoph TAUSCH
Chief Medical Officer, Brust-Zentrum Zürich

Prof. Marc TISCHKOWITZ
Professor of Medical Genetics and Honorary Consultant, Department of Medical Genetics at Cambridge University (UK)

Dr. Séastien TRAN
Médecin Adjoint, Service de Radio-Oncologie, Hôpitaux Universitaires Genève

Prof. Pelagia TSOUTSOU
Médecin cheffe de service, Radio-Oncologie, Hôpitaux Universitaires Genève

Prof. Zsuzsanna VARGA
Leitende Ärztin, Institut für Pathologie, Universitätsspital Zürich

PD Dr. Marcus VETTER
Zentrum Onkologie & Hämatologie Kantonsspital Baselland

Prof. Walter WEBER
Chefarzt Brustchirurgie, Universitätsspital Basel

Prof. Maria WERTLI
Direktorin und Chefärztin Departement Medizin, Kantonsspital Baden

Prof. Isabell WITZEL
Klinikdirektorin Klinik für Gynäkologie, Universitätsspital Zürich

Prof. Sophia ZACKRISSON
Professor and consultant in Radiology Diagnostics, Lund University Cancer Centre (SE)

Dr. Khalil ZAMAN
Médecin adjoint, Service d'oncologie médicale, Médecin responsable du Centre du sein, Centre hospitalier universitaire Vaudois, Lausanne

Dr. Sabine ZEHBE
Radiologie, Brustzentrum Stephanshorn St. Gallen

Kind thanks to our sponsors

Platinum Sponsor Member

Myriad genetics

EndoPredict®
Breast Cancer Prognostic Test

Gold Sponsor Members

AstraZeneca

MSD
INVENTING FOR LIFE

Lilly

Pfizer Oncology

Roche

Silver Sponsor Members

Daiichi-Sankyo | AstraZeneca

EXACT SCIENCES

GILEAD | Oncology

MSD
INVENTING FOR LIFE

Seagen®

Kind thanks to our sponsors

Bronze Sponsor Members

BD

STILLE S&T
exclusively distributed by
Eschenbach MEDICAL

Mecco Medical

SANDOZ A Novartis Division

FURTHER SPONSORS

b-rayZ
AUGMENTING RADIOLOGY

digitalXray

HOLOGIC
The Science of Sure

INCEPTO

intelliMed

Menges Medical
Advancing health

neodynamics

NOVARTIS

SamanTree Medical SA

sirius medical

veracyte

ENHERTU®
trastuzumab deruxtecan

Überlegene Wirksamkeit

Beim HER2+ und HER2-low mBC[1-3]

- **Überlegene Wirksamkeit vs. T-DM1 beim HER2+ 2L mBC[3]**
- **Überlegene Wirksamkeit vs. Chemotherapie* beim HER2-low mBC[2]**
- **Handhabbares Verträglichkeitsprofil[1]**

Hier erfahren Sie mehr zu ENHERTU®:

*Chemotherapie nach Wahl des Arztes (Capecitabin, Eribulin, Gemcitabin, Paclitaxel oder NAB-Paclitaxel).

2L = Zweitlinientherapie; **HER2 =** human epidermal growth factor receptor 2 (humaner epidermaler Wachstumsfaktor-Rezeptor 2); **MBC =** Metastatic breast cancer (metastasierter Brustkrebs); **T-DM1 =** Trastuzumab-Emtansin.

Referenzen: 1. ENHERTU® Fachinformation, www.swissmedicinfo.ch. **2.** Modi S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022 Jul 7;387(1):9-20 (incl. supplementary material). **3.** Cortés J, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386(12):1143-1154 (incl. supplementary material). Fachpersonen können die genannten Referenzen bei Daiichi Sankyo (Schweiz) AG oder AstraZeneca AG anfordern.

Gekürzte Fachinformation Enhertu® 100 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung

Es gibt Fälle von interstitieller Lungenerkrankung (ILD) u./od. Pneumonitis, inklusive tödliche Verläufe. Anzeichen und Symptome müssen umgehend untersucht werden, und Enhertu muss bei ILD/Pneumonitis mit Grad 2 oder höher dauerhaft abgesetzt werden. Patienten mit mässiger Niereninsuffizienz haben ein erhöhtes Risiko für die Entwicklung einer ILD.

Gegen HER2 gerichtetes Antikörper-Wirkstoff-Konjugat. **Z:** Trastuzumab-Deruxtecan 100 mg. **I:** Enhertu als Monotherapie zur Behandlung von erwachsenen Patienten mit inoperablem od. metastasiertem HER2-pos. oder HER2-low (IHC 1+ oder IHC 2+/ISH-) Brustkrebs die wie folgt behandelt wurden: bei HER2-positivem Brustkrebs bereits mind. ein gg. HER2 gerichtetes Behandlungsregime, inkl. Trastuzumab und ein Taxan, sowie eine Progredienz entweder im metastatischen Stadium oder innerhalb von 6 Monaten nach Ende einer adjuvanten od. neoadjuvanten Therapie; bei HER2-low Brustkrebs bereits eine Chemotherapie im metastat. Stadium od. unter adjuvanter Chemotherapie bzw. innerhalb von 6 Monaten nach Abschluss einer adjuvanten Chemotherapie ein Rezidiv ihrer Erkrankung haben. Patienten mit HR+ Brustkrebs müssen darüber hinaus eine endokrine Therapie erhalten haben od. dürfen für eine solche Therapie nicht in Frage kommen. **D:** 5.4 mg/kg 1x alle 3 Wochen, bis zur Progression der Erkrankung od. bis zum Auftreten einer inakzeptablen Toxizität. Für Dosisanpassungen bei Nebenwirkungen u. besonderen Patientengruppen, s. Fachinformation. **KI:** Überempfindlichkeit gg. Wirk-/Hilfsstoffe. **VM:** ILD/Pneumonitis; Neutropenie; Abnahme der linksventrikulären Auswurffraktion; embryofetale Toxizität. **IA:** Keine klin. bedeutsame Wechselwirkung mit Arzneimitteln erwartet, die Inhibitoren von P-Glykoprotein (P-gp)-, MATE2-K-, MRP1- oder BCRP-Transportern od. die Substrate von OAT1- oder OATP1B1-Transportern sind. **Häufige UAW:** Häufigste UAWs: Übelkeit, Erschöpfung, Erbrechen, verminderter Appetit, Anämie, Neutropenie, Alopezie, Obstipation, Diarrhoe, Thrombozytopenie, Leukopenie, Transaminasen erhöht und Muskel-Skelett-Schmerzen. Häufigste schwerwiegende UAWs: ILD/Pneumonitis, Pneumonie, verminderter Appetit, Erbrechen, Übelkeit und Anämie. **P:** Packungen mit 1 Durchstechflasche; Liste: **A. Zul-Inh.:** Daiichi Sankyo (Schweiz) AG, Zürich.

▼ Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Für ausführliche Angaben, siehe http://www.swissmedicinfo.ch. ENH/23/0122_CH-03/2023_DE

ADC/22/0726_CH-03/23_DE

Daiichi-Sankyo | AstraZeneca

Daiichi Sankyo (Schweiz) AG · Vulkanstrasse 106 · Postfach · 8010 Zürich · Switzerland
AstraZeneca AG · Neuhofstrasse 34 · 6340 Baar · Switzerland